ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

Similar documents
INCREASING FUNCTIONALITY AND THE QUALITY OF LIFE THROUGH MEDICAL REHABILITATION IN PATIENTS WITH PARKINSON S DISEASE

The therapeutic benefits of natural therapeutic factors in Baile Tusnad for the rehabilitation of patients with Parkinson s disease

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Rehabilitation for Parkinson's disease: effect of the smile on motor and mental function

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

UNDERSTANDING PARKINSON S DISEASE

Does Resistance Training Improve Mobility in Patients with Parkinson s Disease?

III./3.1. Movement disorders with akinetic rigid symptoms

Evaluation of Parkinson s Patients and Primary Care Providers

VEGETATIVE DISORDERS IN PARKINSON S DISEASE

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease. Sirilak yimcharoen

Exercise as Medicine The Role of Rehabilitation Professionals in Helping to Treat Parkinson's Disease Rehabilitation Services

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Optimizing Clinical Communication in Parkinson s Disease:

Treatment of Parkinson s Disease: Present and Future

Kinematic Modeling in Parkinson s Disease

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Using Sources in the GDP

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

Enhanced Primary Care Pathway: Parkinson s Disease

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

QUALE RIABILITAZIONE NEL FUTURO PER LA MALATTIA DI PARKINSON?

Palladotomy and Pallidal Deep Brain Stimulation

Parkinson s Disease Foundation. Parkinson s Disease Foundation. PD ExpertBriefing: Led By: Ronald F. Pfeiffer, M.D. To hear the session live on:

Postural instability Hypokinesia Rigidity Tremor Forward flexed posture. pain million people 50+ years old 10 most populated countries

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Prior Authorization with Quantity Limit Program Summary

Parkinsons Disease & Movement Disorder Aug 11-13, Frankfurt l Dr. Geeta Shroff

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Motor Fluctuations in Parkinson s Disease

Examination of lalopathy and cognitive function in Parkinson's disease-associated diseases

10th Medicine Review Course st July Prakash Kumar

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Form B3L: UPDRS Part III Motor Examination 1

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s Disease Current Treatment Options

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

A. General features of the basal ganglia, one of our 3 major motor control centers:

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

LINKING EVIDENCE AND PRACTICE. Physical Therapist Interventions for Parkinson Disease Robyn Gisbert, Margaret Schenkman

A. General features of the basal ganglia, one of our 3 major motor control centers:

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

The PD You Don t See: Cognitive and Non-motor Symptoms

Faculty. Joseph Friedman, MD

Parkinson's Disease KP Update

Parkinson s Disease. Gillian Sare

Headway Victoria Epilepsy and Parkinson s Centre

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Evaluation and Management of Parkinson s Disease in the Older Patient

PARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING. Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH

Vague Neurological Disorders

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Do Botulinum Toxin Injections Improve the Freezing of Gait (FOG) Episodes Experienced by Parkinson s Disease (PD) Patients?

2016 Physician Quality Reporting System Data Collection Form: Parkinson s Disease (for patients aged 18 and older)

Identification number: TÁMOP /1/A

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

The PD You Don t See: Cognitive and Non-motor Symptoms

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Differential Diagnosis of Hypokinetic Movement Disorders

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Basal ganglia Sujata Sofat, class of 2009

Appendix N: Research recommendations

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

Comprehensive Approach to DLB Management

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

The Person: Dementia Basics

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS

Helpful Tips for the Unsteady Patient. Mairead Collins Senior Physiotherapist Bon Secours Hospital 20/09/14

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

The Retropulsion Test: A Good Evaluation of Postural Instability in Parkinson s Disease?

Multiple System Atrophy

Parkinson s Foundation

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Detection of Parkinson S Disease by Speech Analysis

Using Resting-State Functional Connectivity of the Basal Ganglia as a Biomarker for Symptoms of Parkinson's Disease

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Managing Movement Disorders in the older patient

symptoms of Parkinson s disease EXCEPT.

Transcription:

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ¹ University of Medicine and Pharmacy Cluj-Napoca ² Clinical Rehabilitation Hospital Cluj-Napoca Abstract Parkinson s disease is a neurodegenerative disorder of the extrapyramidal system, which occurs following the slow and progressive destruction of the pigmented dopaminergic neurons in the brain stem, particularly the substantia nigra and the presence of Lewy bodies. Parkinson s disease has a progressive evolution and its signs and symptoms develop in time. The aim of this study was to analyze the potential role of rehabilitation treatment for the prevention of complications in patients with Parkinson s disease, compared to patients with drug therapy alone. The study included 30 patients aged between 50 and 82 years, divided into two groups: group A, including 15 patients who received both anti-parkinson drug treatment and rehabilitation treatment consisting of massage, kinesiotherapy and occupational therapy, and group B, patients who received only anti-parkinson drug treatment. The duration of treatment was two weeks. The study included patients with stages I-IV (the Hoehn and Yahr scale). The evaluation scale used was the Garden City Scale for the testing of tremor, bradykinesia, stiffness, gait, posture, facies, upper limb balance, speech, vegetative disorders and the self-care ability. At the end of the study, the study group, with rehabilitation treatment, had statistically significant improvements compared to the control group, with drug treatment alone. The highest improvements were found in the items stiffness and bradykinesia, and due to these, the quality of gait was also improved. The exercises for the increase of facial mobility are extremely important, because they improve the verbal and nonverbal communication function. Our data suggest the fact that early individualized rehabilitation treatment plays an important role in the improvement of the quality of life of patients with Parkinson s disease, by the reduction of the degree of disability, the prevention of complications and the increase of the quality of life. Each patient should benefit from rehabilitation treatment that should be continued at home for better results. Keywords Parkinson s disease, Garden City Scale, anti-parkinson therapy, medical rehabilitation in Parkinson s disease 153

Introduction: Parkinson s disease is a major health problem, with medico-social as well as economic implications. It is a neurodegenerative disease of the extrapyramidal system, which occurs following the slow and progressive destruction of pigmented dopaminergic neurons in the brain stem, particularly the substantia nigra and the presence of Lewy bodies [1]. The existence of a nigrostriatal dopaminergic neuronal system, whose disturbance generates many extrapyramidal manifestations (Parkinson s disease), is unanimously recognized [1]. During the course of the disease, many patients encounter mobility difficulties, including transfer, arm mobility and gait difficulties. Due to the frequency of these symptoms, a fear of falling, getting hurt, as well as a loss of independence and inactivity develop, which leads to social isolation and the increase in the risk of osteoporosis and cardiovascular disease [2]. Parkinson s disease causes not only motor disorders such as rest tremor, stiffness, bradykinesia and gait disorders, but also cognitive disorders, autonomous dysfunction: constipation, orthostatic hypotension, postprandial hypotension, perspiration, depression, sleep disorders, dementia. Given that these manifestations occur as early as in stage I of the disease, the idea that these non-motor symptoms are prior to the diagnosis of Parkinson s disease can be supported [4]. There are clear indications that motor disorders cannot be treated with drug therapy alone, which is why the best rehabilitation treatment method must be chosen [5, 6]. The aim of the study is to show the importance and the role of rehabilitation therapy in patients with Parkinson s disease compared to drug therapy and to improve the medical education of patients, through a kinesiotherapy program to be followed at home. Material and method The study included 30 patients aged between 50 and 82 years, diagnosed with Parkinson s disease stages I-IV according to the Hoehn and Yahr classification, who were assigned to two groups. The exclusion criteria were patients with Parkinson s disease stage V and those with contraindications for the physical-kinetic rehabilitation therapy methods. Group A, the study group, included 15 patients who received, in addition to anti- Parkinson drug therapy, rehabilitation therapy. Group B, the control group, included 15 patients who were treated only with drug therapy. This was a prospective study that was carried out at the Clinical Rehabilitation Hospital in the period November 2012 July 2013. In order to establish the degree of physical deficiency, we used for evaluation the Garden City Scale that tested 10 items: tremor, stiffness, bradykinesia, gait, posture, upper limb balance, facies, speech, vegetative disorders, self-care ability. The total score of the scale is obtained by adding up the scores from 0 to 3 for each item; the lower its value, the better the general status of the patient; the maximal score (30) corresponds to a highly disturbed clinicalfunctional status, with multiple dysfunctions. The evaluation test was performed twice, before the beginning of rehabilitation therapy and after the last session. For both groups, the duration of treatment was 10 days. The study group benefited in addition to anti-parkinson medication from rehabilitation therapy consisting of kinesiotherapy, massage and occupational therapy, while for the control group, treatment consisted of anti-parkinson drug therapy. Limitations of the study The major limitation of the study consisted of the short treatment period (10 days). The continuation of an individualized rehabilitation program at the patient s home is recommended. 154

Results After the completion of treatment, the total score of the Garden City Scale in the study group was 210 compared to 267, the total score recorded before treatment. In the control group, the total score of the Garden City Scale was 301 initially, and after treatment it was 291, which was statistically significant (p<0.05). At the final testing, 54% of the patients of group A had improvements, which means a 5 point decrease of the final score compared to the initial score. In the case of moderate improvements, there was a 3 point decrease of the score, and for partial improvements, a 1 point decrease was recorded (Fig. 1). The items for which the highest improvements were obtained were bradykinesia and stiffness. The diagram of bradykinesia showed an increase of the 0-1 score segment from 27% to 60% at the final testing (Fig. 2). The diagram of stiffness showed the following results: the 0-1 score segment increased from 4 to 10 patients, the 1-2 score segment decreased from 9 to 5, and the 2-3 score segment decreased from 2 to 0 patients (Fig. 3). Due to the fact that the rehabilitation program of the study group A also included exercises in the mirror for the mobilization of facial muscles, a 4 point improvement in the facial mimicry score of these patients on the Garden City Scale was recorded (Fig. 4). Following the improvement of the stiffness and bradykinesia items, an improvement in the quality of gait could also be seen in the study group A. Thus, if at the initial testing only 8 patients ranged within the 0-1 score interval, at the final testing, their number increased to 11 (Fig. 5). Conclusions The study shows that rehabilitation treatment associated with drug therapy had a beneficial effect on the quality of life of the patients and the reduction of the degree of disability. The results show that the functions that were best recovered were stiffness and bradykinesia. Due to these two, the quality of gait was also improved. The facial mimicry exercises contributed to the improvement of the verbal and nonverbal communication function of the patients. The initiation of an early individualized therapy helps patients improve their selfcare ability, maintain independence in ADL, and increase their quality of life in a statistically significant proportion compared to those without rehabilitation treatment. The best results were found in patients with less advanced disease, those at stages I and II according to the Hoehn and Yahr classification. Bibliography 1. Prof. Dr. E. Campeanu, Conf. Dr. M. Serban, Curs de neurologie, Institutul de Medicina si Farmacie Cluj-Napoca, Litografia IMF Cluj-Napoca 1989, 374-380. 2. Bloem BR, van Vugt JP, Beckley DJ. Postural instability and falls in Parkinson s disease. Adv Neurol 2001; 87:209-23. 3. Bloem BR, Bhatia KP. Basal ganglia disorders. In: Bronstein AM, Brandt T, Nutt JG, Woollacott MH, editors. Clinical disorders of balance, posture and gait. London: Arnold; 2004. P.173-206. 4. Lliliana Cuibus, M. Pereanu, ***Acta Medica Transilvanica, iunie 2012 2(2): p.12-16, p. 65-66. 5. Keus SHJ, Bloem BR, van Hilten JJ, Ashburn A, Munneke M. Effectiveness of physiotherapy in Parkinson s disease: The feasibility of a randomized controlled trial, Parkinsonism and Related Disorders 13 (2007) 115-121. 6. Kory Calomfirescu, Ş, (1995), Kinetoterapia pacienţilor cu boala Parkinson, Editura Tipografia UMF Cluj- Napoca (p. 23-36, 42-56, 62-64). 155

Fig. 1 Garden City score on day 10 in the two groups. Fig. 2 Evaluation of the bradykinesia score at the initial and final testing for the study group A 156

Fig. 3 Diagram of the stiffness score evaluated on the Garden City Scale Fig. 4 Evaluation of the total facies score on the Garden City Scale Fig. 5 Evaluation of gait on the Garden City Scale 157